Leptin-replacement therapy for lipodystrophy

New England Journal of Medicine

Volumn 346, Issue 8, 2002, Pages 570-578

  Oral, Elif Arioglu ^a   Simha, Vinaya ^c   Ruiz, Elaine ^a   Andewelt, Alexa ^a   Premkumar, Ahalya ^b   Snell, Peter ^c   Wagner, Anthony J ^d   DePaoli, Alex M ^d   Reitman, Marc L ^a   Taylor, Simeon I ^a   Gorden, Phillip ^a   Garg, Abhimanyu ^c  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; FENOFIBRATE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LEPTIN; METFORMIN; RECOMBINANT LEPTIN; TRIACYLGLYCEROL;

ADIPOCYTE; ADOLESCENT; ADULT; ARTICLE; BASAL METABOLIC RATE; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG TOLERABILITY; ENERGY BALANCE; FATTY LIVER; FEMALE; FLUSHING; GLUCOSE METABOLISM; HOMEOSTASIS; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER WEIGHT; NAUSEA; PRIORITY JOURNAL; SELF REPORT; VOMITING;

ADOLESCENT; ADULT; BASAL METABOLISM; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENERGY INTAKE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN RESISTANCE; LEPTIN; LIPODYSTROPHY; LIVER; LIVER FUNCTION TESTS; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 0037148928     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa012437     Document Type: Article

References (42)

1. Positional cloning of the mouse obese gene and its human homologue
2. Serum immunoreactiveleptin concentrations in normal-weight and obese humans
3. Role of leptin in the neuroendocrine response to fasting
4. Congenital leptin deficiency is associated with severe early-onset obesity in humans
5. Effects of recombinant leptin therapy in a child with congenital leptin deficiency
6. Lipoatrophy revisited
7. Lipodystrophy and hepatomegaly with diabetes, lipaemia, and other metabolic disturbances: A case throwing new light on the action of insulin
8. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13
9. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice
10. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
11. The new diagnostic criteria for diabetes: The impact on management of diabetes and macrovascular risk factors
12. Leptin concentrations in the United States: Relations with demographic and anthropometric measures
13. Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy
14. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety)
15. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy
16. Correlation between insulin receptor binding in isolated fat cells and insulin sensitivity in obese human subjects
17. Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire
18. Body composition assessment by dual-energy x-ray absorptiometry: Comparison of prone and supine measurements
19. Estimation of adipose tissue mass by magnetic resonance imaging: Validation against dissection in human cadavers
20. Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy
21. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group
22. Diabetic dyslipidemia
23. Triglyceride as a risk factor for coronary artery disease
24. Lipodystrophies
25. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
26. Lipodystrophic diabetes treated with fenfluramine
27. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes
28. Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks
29. Weight-reducing effects of the plasma protein encoded by the obese gene
30. Effects of the obese gene product on body weight regulation in ob/ob mice
31. Leptin as a therapeutic agent - Trials and tribulations
32. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, doseescalation trial
33. Troglitazone action is independent of adipose tissue
34. Life without white fat: A transgenic mouse
35. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: Model for congenital generalized lipodystrophy
36. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: Genetic and clinical implications
37. Regulation of fatty acid homeostasis in cells: Novel role of leptin
38. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
39. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice
40. The adipocytesecreted protein Acrp30 enhances hepatic insulin action